Web Exclusives

NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.

Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.

At the 2017 Association of Community Cancer Centers Annual Meeting, Tricia Strusowski, RN, MS, Manager, Oncology Solutions, LLC, and project lead of the AONN+ Standardized Metrics Task Force, discussed how the newly released AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.